

Curis Announces Presentations Related to CUDC-907 and Erivedge® at 2016 ASCO Annual Meeting

LEXINGTON, Mass., June 02, 2016 (GLOBE NEWSWIRE) -- Curis, Inc. (Nasdaq:CRIS), a biotechnology company focused on the development and commercialization of innovative and effective therapeutics for the treatment of cancer, today announced that a Phase 2 trials-in-progress poster for CUDC-907, Curis' proprietary drug candidate in development for treatment of patients with relapsed refractory diffuse large B-cell lymphoma (DLBCL) with MYC gene alterations, will be presented at the 2016 American Society of Clinical Oncology (ASCO) Annual Meeting to be held from June 3-7 in Chicago, IL.

In addition, data will be presented from clinical studies of Erivedge®, a first-in-class drug approved for the treatment of patients with advanced basal cell carcinoma (BCC). Roche and Genentech, a member of the Roche Group, develop and commercialize Erivedge under a collaboration agreement with Curis.

Additional information on the presentations can be found below and abstracts can be accessed at www.asco.org.

CUDC-907 Poster Presentation:

Date/Time: Monday, June 6, 8 AM — 11:30 AM CDT
Abstract Number: TPS7579
Phase 2, open-label study of CUDC-907 with and without rituximab in patients with relapsed/refractory MYC-altered diffuse large B cell lymphoma
Presentation Title: lymphoma

Erivedge® Poster Presentations:

Date/Time: **Poster Session: Saturday, June 4, 1 PM — 4:30 PM CDT**
Poster Discussion Session: Saturday, June 4, 4:45 PM — 6 PM CDT
Abstract Number: 9509
Mikie: A randomized, double-blinded, regimen-controlled, phase 2 study to assess the efficacy and safety of two different vismodegib (VISMO) regimens in patients (pts) with multiple basal cell carcinomas (BCCs)
Presentation Title: carcinomas (BCCs)

Date/Time: **Saturday, June 4, 1 PM — 4:30 PM CDT**
Abstract Number: 9532
Vismodegib (VISMO), a hedgehog pathway inhibitor (HPI), in advanced basal cell carcinoma (aBCC): STEVIE study primary analysis in 1215 patients (pts)
Presentation Title: analysis in 1215 patients (pts)

About Curis, Inc.

Curis is a biotechnology company focused on the development and commercialization of innovative drug candidates for the treatment of human cancers, including CUDC-907, which is being investigated in two clinical studies in patients with lymphomas and solid tumors. Curis is also engaged in a broad collaboration with Aurigene in the areas of immuno-oncology and precision oncology. As part of this collaboration, Curis has exercised options to exclusively license oral small molecule antagonists of PD-L1/ VISTA and IRAK4. Curis is also party to a collaboration with Genentech, a member of the Roche Group, under which Genentech and Roche are developing and commercializing Erivedge® for the treatment of advanced basal cell carcinoma. For more information, visit Curis' website at www.curis.com.

For More Information:

James E. Dentzer
Chief Financial Officer & Chief Administrative Officer
Curis, Inc.
617-503-6597
jdentzer@curis.com

Media Contact
David Schull
Russo Partners
(212) 845-4271
david.schull@russopartnersllc.com

<https://investors.curis.com/Curis-Announces-Presentations-Related-to-CUDC-907-and-Erivedge-R-at-2016-ASCO-Annual-Meeting>